Zafgen Inc. Attempts To Double After Positive Results For Obesity Drug

Zafgen Inc. ZFGN shares are trading higher by $4.48 at $10.10 in Wednesday's session. The Street is rewarding the company for its Phase 3 obesity trial that achieved co-primary efficacy endpoint. After a sharply higher open, it retreated only $0.13 to $7,33 before resuming its move higher. So far, the issue has reached $11.88 before falling back its current level. The issue has been attempting to recover from the drubbing it took on December 2, when it fell from $15.93 to $6.28. the catalyst for that decline a was a patient death in a clinical update for Beforanib.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: TechnicalsIntraday UpdateMoversTrading Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!